Showing 771-780 of 7314 results for "".
Buyer Beware: CBD Products May Peddle False Hope Amid Corona Fears
https://practicaldermatology.com/series/dermatology-dispatches/buyer-beware-cbd-products-may-peddle-false-hope-amid-corona-fears/19775/Any claims that a medical cannabinoid-based product can kill COVID-19 are “absolutely unsubstantiated,” warns Adam Friedman, MD. There is no evidence that these products contain any antiviral properties, and patients should be advised against believing such claims.2018 Therapeutics and Device Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-2018-therapeutics-and-device-highlights/18374/2018 saw new approvals and clearances for acne, impetigo, psoriasis, and skin cancer from Ortho Dermatologics, Sun Pharma, Cutanea, and more. Plus, updates for Restylane, new devices from BTL, Cutera, and others.DermWireTV: AAD Virtual Data Highlights, Cynosure Consumer Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-aad-virtual-data-highlights-cynosure-consumer-data/19818/The American Academy of Dermatology 2020 VMX Virtual Conference shines a light on fresh data from UCB, Leo Pharma, Lilly and Dermira, and Soliton. Cassiopea reports long-term data for Clascoterone. Zilxi from Menlo and Foamix approved for rosacea. Cynosure reports positive cosmetic consumer outlookDermWireTV: Cosmetic Surgery Forum Highlights, LEO Focuses on AD
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-cosmetic-surgery-forum-highlights-leo-focuses-on-ad/19703/New treatments and medical controversies take center stage at Cosmetic Surgery Forum as the meeting moves to Nashville in its 11th Year. Leo Pharma’s tralokinumab meets all primary and secondary endpoints in three pivotal Phase 3 studies for the treatment of adults with moderate-to-severe atopic derHow does chronic AD histopathology evolve from spongiosis-dominant lesions to lichenified, fibrotic plaques?
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/how-does-chronic-ad-histopathology-evolve-from-spongiosis-dominant-lesions-to-lichenified-fibrotic-plaques/48772/Christopher Bunick, MD, FAAD, discusses the roles of the six major cytokines that drive atopic dermatitis pathophysiology: IL-4, IL-13, IL-31, TSLP, IL-22, and IFN-γ.Drs. Rosen and Bhatia Highlight Latest Drugs at Maui Derm
https://reachmd.com/programs/practical-dermatology/drs-rosen-and-bhatia-highlight-latest-drugs-at-maui-derm/32914/The current landscape of therapeutics for dermatologic conditions is dramatic, with new groundbreaking drugs continuously becoming available.Jet Assisted Fat Transfer on Face and Hands
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/jet-assisted-fat-transfer-on-face-and-hands/19391/LIVE Patient DemonstrationHow to Choose the Right Filler
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/how-to-choose-the-right-filler/19411/Dr. Amy Derick reviews key points about injectable fillers, a non-invasive alternative to surgical facelifts.Galderma FCBCure SoS Hub Chovatiya Video 2
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/galderma-fcbcure-sos-hub-chovatiya-video-2/56736/Raj Chovatiya, MD, PhD, MSCI, FAAD, discusses whether barrier dysfunction drives inflammation and immune dysregulation, or vice versa, or both, in atopic dermatitis.Heather Woolery-Lloyd, MD - SKIN MINUTE
https://practicaldermatology.com/series/skin-minute/heather-woolery-lloyd-md-skin-minute/56411/TBD